Germany· DE-A57-6a43c19a3c757616
Silodosin Ipca
A silodosin product containing silodosin, registered in Germany by Ipca Productos Farmaceuticos Unipessoal Lda. The same ATC class is registered in 17 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Silodosin is registered in 17 of 19 countries.
Countries holding a registration under ATC G04CA04 (silodosin), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 10 of them publish a price we can compare per daily dose
Silodosin · ATC G04CA04
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of silodosin costs, country by country.
Normalised to the WHO defined daily dose (8 mg), the median price runs from $0.28 in Italy to $1.39 in Switzerland — a ×5.0 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Silodosin · price per daily dose (8 mg)
USD · FX 28 Sept 2026
- CH Switzerland$1.39
- IT Italy$0.28
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Silodosin
- Manufacturer
- Ipca Productos Farmaceuticos Unipessoal Lda
- Country
- Germany (DE)
- ATC code
- G04CA04
- ATC class
- Silodosin
- Defined daily dose
- 8 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
148 interactions on record for silodosin.
Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Silodosin · interactions on record
148 records
- 9 severe
- 139 moderate
Most severe, free to view
- KetoconazoleH02CA03severe
- ClarithromycinJ01FA09severe
- KetoconazoleJ02AB02severe
- Darunavir and cobicistatJ05AR14severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under G04CA04
Silodosin, as other registers publish it.
- CanadaAURO-SILODOSINAURO PHARMA INC
- CanadaAURO-SILODOSINAURO PHARMA INC
- CanadaJAMP SILODOSINJAMP PHARMA CORPORATION
- CanadaJAMP SILODOSINJAMP PHARMA CORPORATION
- CanadaPMS-SILODOSINPHARMASCIENCE INC
- CanadaPMS-SILODOSINPHARMASCIENCE INC
- United KingdomRapaflo 4mg capsulesImported (Canada)
- United KingdomRapaflo 8mg capsulesImported (Canada)
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/cc767bfa-f748-4ec0-baa9-3fa570fcb9b6 GET /v1/drugs/cc767bfa-f748-4ec0-baa9-3fa570fcb9b6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Silodosin",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about silodosin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.